Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

This article is all about what’s new and what it might mean for us, covering the latest in genetics in news. New methods like ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Sofi-cel is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial (T-RRex) for patients with relapsed or refractory (R/R) ...

By stripping two metabolic enzymes, scientists created a mycoprotein that needs less energy, emits less carbon, and rivals ...

Biotech startup CrisprBits uses CRISPR-based techniques to change the shape of diagnostics by decoding genetic sequencing ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Ultrastructure expansion microscopy revealed that defective centrioles hinder sperm motility by impeding flagellum formation ...